Mike earned a PhD in Medicinal Chemistry from the University of Minnesota and moved immediately into big pharma where over the span of 25+ years he has worked locally and internationally delivering pre-clinical and clinical milestones across several target classes. Working with world class discovery groups at Upjohn/Pharmacia/Pfizer, Marion Merrell Dow/Aventis and Eli Lilly he has advanced projects in Infectious Diseases, Cardiovascular, Metabolic Diseases and Autoimmune therapeutic areas.
He has been involved with preclinical medicinal chemistry from target identification to candidate selection and phase I clinical planning. Furthermore, his experience across several therapeutic areas has allowed him the opportunity to repurpose chemistry to support indications where common pathways exist. He is an inventor on numerous patents and has a strong publication record.
His interest in Recursion stems from a long time call to deliver high value medicines to help others and he believes the novel technology (AI and phenotypic assays) at Recursion combined with an aggressive medicinal chemistry approach will create opportunities that up until recently have eluded drug discovery scientists.
In his free time Mike enjoys spending time with friends and family, fishing, skiing and exploring the outdoors.
Are you Recursion ready?
Join our passionate, innovative team—and help us realize our goal of 100 treatments by 2025.